# Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

> **NCT00408434** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 32 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** CS-7017

## Key facts

- **NCT ID:** NCT00408434
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408434, "Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00408434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*